Rosendo BN, Arceo GMA, Carranza MJ

Language: Spanish
References: 20
Page: 421-430
PDF size: 246.06 Kb.

ABSTRACT

Background: The metabolic syndrome is a cluster of factors for cardiovascular disease. The main physiopathogenic mechanisms of the metabolic syndrome are obesity and insulin resistance. Recently the international organisms have suggested that metabolic syndrome is a high cardiovascular risk condition. However it has not been done a trial to assess the effect of global treatment of metabolic syndrome and its impact on the cardiovascular risk levels after therapeutic intervention.
Objectives:To determine the cardiovascular risk of patients with metabolic syndrome according to the NCEP criteria, to establish the influence of the treatment of metabolic syndrome components on cardiovascular risk levels and to determine the presence of insulin resistance in the patients with MS and its modification with the treatment for metabolic syndrome components.
Patient and Methods: We studied 194 patients, 40 of them received treatment for at least one year. We applied the cardiovascular risk assessment before and after a year of treatment using the cardiovascular risk charts of the ESH, in the 2007 version. The treatment was diet and physical activity recommendations as well as specific drugs for the risk factors that the patient presented at the first evaluation.
Results: The baseline cardiovascular risk was distributed as the following: 0% low risk, 32% moderate risk, 63% high risk, 5% very high risk. After a year with treatment the cardiovascular risk distribution was 18% low risk, 51% moderate risk, 31% high risk, 0% very high risk. The significant changes were in waist circumference(p=0.027), systolic blood pressure (p=0.002), total cholesterol (p=0.0001), triglycerides (p=0.0001), HDL-C (p=0.008) and LDL-C (p=0.006). The reduction in insulin resistance was only achieved by the patients with low cardiovascular risk after treatment.
Conclusions: Intensive treatment of metabolic syndrome significantly decreases cardiovascular risk and insulin resistance.

REFERENCES

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.

2. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet 2005;366:1059-1062.

3. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53(8):2087-2094.

4. Anderson PJ, Critchley JAJH, Chan JCN, et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. International Journal of Obesity 2001;25:1782.

5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005;13:322-327.

6. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. JCEM 2001;86:5457-5464.

7. Carranza J, Alvizouri M, Rodríguez A, Campos Y, et al. Lower quantities of avocado as daily source of monounsaturated fat: effect on serum and membrane lipids,endothelial function, platelet aggregation and c-reactive protein in patients with metabolic syndrome. Med Int Mex 2004;20:417-424.

8. World Health Organization-International Society of Hypertension Guidelines for the management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17:151-183.

9. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. European Heart Journal Advance Access published June 11, 2007.

10. Cardona-Muñoz EG, Carranza-Madrigal J, Hernández y Hernández H. Tratamiento. Modificaciones del estilo de vida. Tratamiento farmacológico. Actualización del Consenso Nacional de Hipertensión Arterial. Med Int Mex 2006;22:55-63.

11. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.

12. Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular diseases and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-391.

13. American Diabetes Association. Aspirin Therapy in Diabetes. Diabetes Care 2004; 27(suppl 1):S72-S73.

14. Martín-Baranera M, et al. Estratificación y grado de control del riesgo cardiovascular en la población hipertensa española. Resultados del estudio DICOPRESS. Med Clin (Barc) 2007;129(7):247-251.

15. Phelan S, et al. Weight loss and metabolic syndrome. International Journal of Obesity 2007;(31):1442-1448.

16. Ochodnicky P, et al. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006;47 [Suppl 2]:S151-S162.

17. Parving HH, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney International 2006;69: 2057-2063.

18. 18, Abdel-Maksoud, et al. Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes. J Cardiovasc Pharmacol 2008;51:331-351.

19. Patel TN, Mehdi H, Deepak BL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart Journal 2007;28(6):664-672.

20. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. European Heart Journal Advance Access published June 11, 2007.